To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer (NCT05802342) | Qilu Pharmaceutical Co., Ltd. | 2023-04-20 |
Track To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients automatically
Every clearance here is in the API, with alerts when new ones post.